microRNA-135a-5p regulates NOD-like receptor family pyrin domain containing 3 inflammasome-mediated hypertensive cardiac inflammation and fibrosis via thioredoxin-interacting protein

References

• Aras MA, Psotka MA, De Marco T. Pulmonary hypertension due to left heart disease: an update. Curr Cardiol Rep. 2019;21:62.
   PubMed Web of Science ®Google Scholar
• Kokubo Y, Matsumoto C. Hypertension is a risk factor for several types of heart disease: review of prospective studies. Adv Exp Med Biol. 2017;956:419–426.
   PubMed Web of Science ®Google Scholar
• Tichelbacker T, Dumitrescu D, Gerhardt F, et al. Pulmonary hypertension and valvular heart disease. Herz. 2019;44:491–501.
   PubMed Web of Science ®Google Scholar
• Stacey RB, Hundley WG. Integrating measures of myocardial fibrosis in the transition from hypertensive heart disease to heart failure. Curr Hypertens Rep. 2021;23:22.
   PubMed Web of Science ®Google Scholar
• Schelbert EB. Myocardial scar and fibrosis: the ultimate mediator of outcomes?. Heart Fail Clin. 2019;15:179–189.
   PubMed Web of Science ®Google Scholar
• Espeland T, Lunde IG, and Ha B, et al. Myocardial fibrosis. Tidsskr Nor Laegeforen. 2018;138. doi:10.4045/tidsskr.17.1027.
   Web of Science ®Google Scholar
• Shenasa M, Shenasa H. Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol. 2017;237:60–63.
   PubMed Web of Science ®Google Scholar
• Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. EMBO Mol Med. 2020;12:e10865.
   PubMed Web of Science ®Google Scholar
• Shao BZ, Xu ZQ, Han BZ, et al. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang S, Xiao Y, et al. NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev. 2020;2020:4063562.
   PubMed Web of Science ®Google Scholar
• De Miguel C, Pelegrin P, Baroja-Mazo A, et al. Emerging role of the inflammasome and pyroptosis in hypertension. Int J Mol Sci. 2021;22:1064.
   PubMed Web of Science ®Google Scholar
• Pinar AA, Scott TE, Huuskes BM, et al. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacol Ther. 2020;209:107511.
   PubMed Web of Science ®Google Scholar
• Liang Q, Cai W, Zhao Y, et al. Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis. Pharmacol Res. 2020;158:104884.
   PubMed Web of Science ®Google Scholar
• Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66:1037–1046.
   PubMed Web of Science ®Google Scholar
• Wu M, Han W, Song S, et al. NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice. Mol Cell Endocrinol. 2018;478:115–125.
   PubMed Web of Science ®Google Scholar
• Song W, Zhang T, Yang N, et al. Inhibition of micro RNA miR-122-5p prevents lipopolysaccharide-induced myocardial injury by inhibiting oxidative stress, inflammation and apoptosis via targeting GIT1. Bioengineered. 2021;12:1902–1915.
   PubMed Web of Science ®Google Scholar
• Pan J, Xu Z, Guo G, et al. Circ_nuclear factor I X (circNfix) attenuates pressure overload-induced cardiac hypertrophy via regulating miR-145-5p/ATF3 axis. Bioengineered. 2021;12:5373–5385.
   PubMed Web of Science ®Google Scholar
• Ding Y, Wang J, Lu J. miR-337-5p promotes the development of cardiac hypertrophy by targeting Ubiquilin-1 (UBQLN1). Bioengineered. 2021;12:6771–6781.
   PubMed Web of Science ®Google Scholar
• Wang S, Cheng Z, Chen X, et al. microRNA-135a protects against myocardial ischemia-reperfusion injury in rats by targeting protein tyrosine phosphatase 1B. J Cell Biochem. 2019;120:10421–10433.
   PubMed Web of Science ®Google Scholar
• Feng H, Xie B, Zhang Z, et al. MiR-135a protects against myocardial injury by targeting TLR4. Chem Pharm Bull (Tokyo). 2021;69:529–536.
   PubMed Web of Science ®Google Scholar
• Chen C, Shen H, Huang Q, et al. The circular RNA CDR1as regulates the proliferation and apoptosis of human cardiomyocytes through the miR-135a/HMOX1 and miR-135b/HMOX1 axes. Genet Test Mol Biomarkers. 2020;24:537–548.
   PubMed Web of Science ®Google Scholar
• Wei Y, Wu Y, Feng K, et al. Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-beta/Smads pathway. J Ethnopharmacol. 2020;249:112404.
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu Y, Pan Y, et al. MicroRNA-135a inhibits cardiac fibrosis induced by isoproterenol via TRPM7 channel. Biomed Pharmacother. 2018;104:252–260.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li YP, Xiao LM, et al. Extracellular vesicles derived from M2 microglia reduce ischemic brain injury through microRNA-135a-5p/TXNIP/NLRP3 axis. Lab Invest. 2021;101:837–850.
   PubMed Web of Science ®Google Scholar
• Ferreira NE, Omae S, Pereira A, et al. Thioredoxin interacting protein genetic variation is associated with diabetes and hypertension in the Brazilian general population. Atherosclerosis. 2012;221:131–136.
   PubMed Web of Science ®Google Scholar
• Rao Y, Chen J, Guo Y, et al. Rivaroxaban ameliorates angiotensin II-induced cardiac remodeling by attenuating TXNIP/Trx2 interaction in KKAy mice. Thromb Res. 2020;193:45–52.
   PubMed Web of Science ®Google Scholar
• Guide for the care and use of laboratory animals. 8th. Washington (DC); 2011. doi:10.17226/12910.
   Google Scholar
• Watanabe K, Narumi T, Watanabe T, et al. The association between microRNA-21 and hypertension-induced cardiac remodeling. PLoS One. 2020;15:e0226053.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang H, Li Z, et al. microRNA-130a-5p suppresses myocardial ischemia reperfusion injury by downregulating the HMGB2/NF-kappaB axis. BMC Cardiovasc Disord. 2021;21:121.
   PubMed Web of Science ®Google Scholar
• Lyu L, Chen J, Wang W, et al. Scoparone alleviates Ang II-induced pathological myocardial hypertrophy in mice by inhibiting oxidative stress. J Cell Mol Med. 2021;25:3136–3148.
   PubMed Web of Science ®Google Scholar
• Meng J, Qin Y, Chen J, et al. Treatment of hypertensive heart disease by targeting Smad3 signaling in mice. Mol Ther Methods Clin Dev. 2020;18:791–802.
   PubMed Web of Science ®Google Scholar
• Meijles DN, Cull JJ, Markou T, et al. Redox regulation of cardiac ASK1 (Apoptosis Signal-Regulating Kinase 1) controls p38-MAPK (Mitogen-Activated Protein Kinase) and orchestrates cardiac remodeling to hypertension. Hypertension. 2020;76:1208–1218.
   PubMed Web of Science ®Google Scholar
• Li T, Chen Y, Li Y, et al. FAM134B-mediated endoplasmic reticulum autophagy protects against sepsis myocardial injury in mice. Aging (Albany NY). 2021;13:13535–13547.
   PubMedGoogle Scholar
• Huang XR, Chung AC, Yang F, et al. Smad3 mediates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling. Hypertension. 2010;55:1165–1171.
   PubMed Web of Science ®Google Scholar
• Wang F, Trial J, Diwan A, et al. Regulation of cardiac fibroblast cellular function by leukemia inhibitory factor. J Mol Cell Cardiol. 2002;34:1309–1316.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang Q, Feng Y, et al. MicroRNA-26a protects the heart against hypertension-induced myocardial fibrosis. J Am Heart Assoc. 2020;9:e017970.
   PubMed Web of Science ®Google Scholar
• Zhao M, Yang Y, Li J, et al. Silencing of OIP5-AS1 protects endothelial cells from ox-LDL-triggered injury by regulating KLF5 expression via sponging miR-135a-5p. Front Cardiovasc Med. 2021;8:596506.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92–97.
   PubMed Web of Science ®Google Scholar
• Li Z, Guo Z, Lan R, et al. The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy. Acta Pharm Sin B. 2021;11:1286–1299.
   PubMed Web of Science ®Google Scholar
• Gan W, Ren J, Li T, et al. The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1–10.
   PubMed Web of Science ®Google Scholar
• Chen D, Dixon BJ, Doycheva DM, et al. IRE1alpha inhibition decreased TXNIP/NLRP3 inflammasome activation through miR-17-5p after neonatal hypoxic-ischemic brain injury in rats. J Neuroinflammation. 2018;15:32.
   PubMed Web of Science ®Google Scholar
• Mouton AJ, Li X, Hall ME, et al. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation. Circ Res. 2020;126:789–806.
   PubMed Web of Science ®Google Scholar
• Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29:1–6.
   PubMed Web of Science ®Google Scholar
• Verjans R, Peters T, Beaumont FJ, et al. MicroRNA-221/222 family counteracts myocardial fibrosis in pressure overload-induced heart failure. Hypertension. 2018;71:280–288.
   PubMed Web of Science ®Google Scholar
• Xu JJ, Zheng WH, Wang J, et al. Long non-coding RNA plasmacytoma variant translocation 1 linked to hypoxia-induced cardiomyocyte injury of H9c2 cells by targeting miR-135a-5p/forkhead box O1 axis. Chin Med J (Engl). 2020;133:2953–2962.
   PubMed Web of Science ®Google Scholar
• Wang X, Cheng Z, Xu J, et al. Circular RNA Arhgap12 modulates doxorubicin-induced cardiotoxicity by sponging miR-135a-5p. Life Sci. 2021;265:118788.
   PubMed Web of Science ®Google Scholar
• Yu Y, Hu LL, Liu L, et al. Hsp22 ameliorates lipopolysaccharide-induced myocardial injury by inhibiting inflammation, oxidative stress, and apoptosis. Bioengineered. 2021;12:12544–12554.
   PubMed Web of Science ®Google Scholar
• Hanna A, Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 2020;34:849–863.
   PubMed Web of Science ®Google Scholar
• Jin D, Han F. FOXF1 ameliorates angiotensin II-induced cardiac fibrosis in cardiac fibroblasts through inhibiting the TGF-beta1/Smad3 signaling pathway. J Recept Signal Transduct Res. 2020;40:493–500.
   PubMed Web of Science ®Google Scholar
• Chen X, Xiao Z, and Jiang Z, et al. Schisandrin B attenuates airway inflammation and airway remodeling in asthma by inhibiting NLRP3 inflammasome activation and reducing pyroptosis. Inflammation. 2021;44(6): 2217–2231.
   PubMed Web of Science ®Google Scholar
• Xie B, Lu C, Chen C, et al. miR-135a alleviates silica-induced pulmonary fibrosis by targeting NF-kappaB/inflammatory signaling pathway. Mediators Inflamm. 2020;2020:1231243.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang G, Sun B, et al. Activation of NLR family, domain of pyrin containing 3 inflammasome by nitrous oxide through thioredoxin-interacting protein to induce nerve cell injury. Bioengineered. 2021;12:4768–4779.
   PubMed Web of Science ®Google Scholar
• Han -Y-Y, Gu X, Yang C-Y, et al. Protective effect of dimethyl itaconate against fibroblast–myofibroblast differentiation during pulmonary fibrosis by inhibiting TXNIP. J Cell Physiol. 2021;236(11):7734–7744.
   PubMed Web of Science ®Google Scholar
• Park HS, Song JW, Park JH, et al. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. Autophagy. 2021;17:2549–2564.
   PubMed Web of Science ®Google Scholar